This study aims to determine the safety, preliminary antitumor activity, and pharmacokinetics (PK) of RYZ101 in combination with standard of care (SoC) therapy consisting of carboplatin + etoposide + atezolizumab in untreated subjects with somatostatin receptor expressing (SSTR+) ES-SCLC.
SCLC,Extensive Stage
This study aims to determine the safety, preliminary antitumor activity, and pharmacokinetics (PK) of RYZ101 in combination with standard of care (SoC) therapy consisting of carboplatin + etoposide + atezolizumab in untreated subjects with somatostatin receptor expressing (SSTR+) ES-SCLC.
Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC
-
Research Facility, Los Angeles, California, United States, 90024
Research Facility, San Francisco, California, United States, 94158
Research Facility, Jacksonville, Florida, United States, 32224
Research Facility, Orlando, Florida, United States, 32806
Research Facility, Grand Rapids, Michigan, United States, 49503
Research Facility, Troy, Michigan, United States, 48098
Research Facility, Rochester, Minnesota, United States, 55905
Research Facility, Omaha, Nebraska, United States, 68130
Research Facility, Houston, Texas, United States, 77090
Research Facility, Salt Lake City, Utah, United States, 84112
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
RayzeBio, Inc.,
Denise Ferreira, MD, STUDY_DIRECTOR, RayzeBio, Inc.
2026-12